DURVALUMAB and RASH

Overview

RASH is the #11 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 387 FDA adverse event reports linking DURVALUMAB to RASH. This represents approximately 1.7% of all 23,251 adverse event reports for this drug.

Patients taking DURVALUMAB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RASH is a less commonly reported adverse event for DURVALUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of DURVALUMAB

In addition to rash, the following adverse reactions have been reported for DURVALUMAB:

• DEATH — 3,167 reports
• MALIGNANT NEOPLASM PROGRESSION — 1,390 reports
• PNEUMONITIS — 819 reports
• RADIATION PNEUMONITIS — 793 reports
• PYREXIA — 574 reports
• DIARRHOEA — 538 reports
• OFF LABEL USE — 481 reports
• DYSPNOEA — 435 reports
• INTERSTITIAL LUNG DISEASE — 432 reports
• PNEUMONIA — 413 reports

Other Drugs Associated with RASH

The following drugs have also been linked to rash in FDA adverse event reports:

Does DURVALUMAB cause RASH?

RASH has been reported as an adverse event in 387 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RASH with DURVALUMAB?

RASH accounts for approximately 1.7% of all adverse event reports for DURVALUMAB, making it a notable side effect.

What should I do if I experience RASH while taking DURVALUMAB?

If you experience rash while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages